Extracervical approaches for thyroidectomy are seldom explored in the western population. The objective of this study was to evaluate the outcomes of hemithyroidectomy via endoscopic unilateral axillo-breast approach (UABA) with gas insufflation. Consecutive patients undergoing UABA hemithyroidectomy for symptomatic benign or cytologically indeterminate nodules (Bethesda III lesions) of less than 5 cm from July 2015 to December 2020 at three European institutions were included. Patients were excluded if presenting with a BMI more than 25 kg/m2, had previous neck surgery and/or radiation, had bilateral thyroid lesions, retrosternal goitre, Hashimoto thyroiditis or Graves’ disease. Follow-up was carried out at 2 weeks, 3 months and 1 year. Outcomes of interest were surgical (including operating time, mean duration of hospital stay and complications) and self-assessed cosmetic outcomes. Out of 984 patients treated with hemithyroidectomy during the study interval, 253 were selected, including 214 women and 39 men. Patients’ mean age was of 46.6 years with a mean BMI of 22.57. Mean operating time was 72.9 minutes. A transient recurrent laryngeal nerve injury was reported in 3.6 per cent of the patients, but none was persistent. Transient pectoral/cervical hypoesthesia was noted in 24.1 per cent of patients, with no permanent hypoesthesia. Skin burns and subcutaneous hematoma developed in 2.4 per cent and 2 per cent of patients but resolved within the third month after surgery. There was no tracheal/oesophageal perforation, conversion to open surgery or reoperation. The final pathology revealed 241 benign nodules, nine underlying papillary thyroid carcinomas, and three cases of follicular carcinoma. Hospital discharge was achieved on the first in 68.8 per cent of the patients and on the second postoperative day in 31.2 per cent of the cases. All patients were satisfied with the cosmetic aspect. In selected patients, UABA with gas insufflation for hemithyroidectomy could be performed for the treatment of unilateral thyroid pathologies.
Robot-assisted surgery has revolutionized minimally invasive procedures, offering superior three-dimensional visualization and mobile instruments suitable for smaller areas. For this reason, robotic retroperitoneal adrenalectomy (RRA) is emerging as an ideal procedure for this technology. This study aimed to assess the outcomes of the first 10 consecutive cases of this procedure using the RAS Hugo™ platform. Conducted between July 2023 and February 2024, the surgeries were performed with patients in the prone position, accessing the retroperitoneal space using standard endoscopic techniques. High-energy sealing instruments were utilized for adrenal vein sectioning, and specimens were extracted using protective bags. Ten surgical interventions were performed, with six male patients and four female patients. Most patients underwent surgery due to suspected primary hyperaldosteronism ( n =7), while the remainder were operated on for Cushing’s syndrome ( n =3). Median patient age was 58 years (range 50–73) with a median BMI of 28.5 kg/m 2 (range 21–36), and American Society of Anaesthesiologists (ASA) risk scores were evenly split between ASA II and ASA III. Lesions were equally distributed between the right and left adrenal glands, with a median tumor size of 1.5 cm (range 0.5–3.5). Median operative time was 124.5 min (range 102–198), with one case requiring conversion to endoscopic approach due to pyelonephritis. No postoperative complications were reported, and median hospital stay was 1 day (range 1–3). RRA demonstrates feasibility for selected patients, offering enhanced image resolution and precision in confined spaces. However, challenges such as increased operative time and the need for skilled teams warrant consideration.
1 December 2014 in Cirugía Española (English Edition)